Basic Information
| Drug ID | DDPD00195 |
|
| Drug Name | Betaxolol | |
| Molecular Weight | 307.4278 | |
| Molecular Formula | C18H29NO3 | |
| CAS Number | 63659-18-7 | |
| SMILES | CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1 | |
| External Links | ||
| DRUGBANK | DB00195 | |
| PubChem Compound | 2369 | |
| PDR | 1084 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Caco-2 Permeability | -4.81 | - | -4.81 | - | ADME Research, USCD |
| Log P | 2.81 | - | 2.81 | - | RECANATINI,M (1992) |
| Melting Point | 71.0 | ℃ | 70-72 | ℃ | PhysProp |
| Water Solubility | 451.0 | mg/L | 451 | mg/L | DRUGBANK |
| pKa | 9.4 | - | 9.4 | - | DRUGBANK |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Reference |
|---|---|---|---|---|---|---|
| Absorption | 100.0 | % | 100.0 | % | PO, oral; | DRUGBANK |
| Bioavailability | 89.0 | % | >89 | % | PO, oral; | DRUGBANK |
| Metabolic | 85.0 | % | 85 | % | Liver metabolism; | DRUGBANK |
| Clearance | 0.20 | L/h/kg | 3.4 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 4.8 | L/kg | 4.8 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 18.0 | h | 14-22 | h | DRUGBANK | Half-life | 17.0 | h | 17 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Toxicity LD50 | 375.0 | mg/kg | 350-400 | mg/kg | PO, oral; mouse; | DRUGBANK | Toxicity LD50 | 920.0 | mg/kg | 860-980 | mg/kg | PO, oral; Rattus, Rat; | DRUGBANK |
| Protein Binding | 50.0 | % | 50 | % | DRUGBANK |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for children | 2.0 | drop/day | 2 | drop/day | ophthalmic administration | Betoptic S | betaxolol hydrochloride | PDR |
| Max dose for adolescents | 2.0 | drop/day | 2 | drop/day | ophthalmic administration | Betoptic S | betaxolol hydrochloride | PDR |
| Max dose for adults | 20.0 | mg/day | 20 | mg/day | PO, oral | Betoptic S | betaxolol hydrochloride | PDR |
| Max dose for adults | 4.0 | drop/day | 4 | drop/day | ophthalmic administration | Betoptic S | betaxolol hydrochloride | PDR |
| Max dose for adults | 2.0 | drop/day | 2 | drop/day | ophthalmic administration | Betoptic S | betaxolol hydrochloride | PDR |
| Max dose for elderly | 20.0 | mg/day | 20 | mg/day | PO, oral | Betoptic S | betaxolol hydrochloride | PDR |
| Max dose for elderly | 4.0 | drop/day | 4 | drop/day | ophthalmic administration | Betoptic S | betaxolol hydrochloride | PDR |
| Max dose for elderly | 2.0 | drop/day | 2 | drop/day | ophthalmic administration | Betoptic S | betaxolol hydrochloride | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1